Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Vistusertib||AZD2014|AZD-2014||mTOR Inhibitor 51||Vistusertib (AZD2014) is an ATP-competitive inhibitor of mTOR, which may result in tumor growth inhibition (PMID: 23375793, PMID: 31707687).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Vistusertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Vistusertib (AZD2014) induced apoptosis and decreased viability of colorectal cancer cell lines in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24309100).||24309100|
|PDGFRA act mut||pancreatic cancer||predicted - sensitive||Vistusertib||Phase I||Actionable||In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799).||25805799|
|STK11 loss||lung non-small cell carcinoma||no benefit||Vistusertib||Clinical Study - Cohort||Actionable||In a Phase II trial (NLMT), Vistusertib (AZD2014) treatment resulted in an observed objective response rate (ORR) of 0% (0/17), durable clinical benefit rate (DCBR) of 12% (2/17), and medial progression-free survival (PFS) of 2.3 months in patients with non-small cell lung cancer harboring STK11 loss, with Bayesian posterior probability for OR and DCBR of <0.01 and 0.06, respectively, thus the cohort was closed due to futility (PMID: 32669708, NCT02664935).||32669708|
|ERBB2 act mut||estrogen-receptor positive breast cancer||predicted - sensitive||Vistusertib||Phase I||Actionable||In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799).||25805799|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03071874||Phase II||Vistusertib||Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas||Active, not recruiting||USA||0|
|NCT02403895||Phase II||Vistusertib Paclitaxel||AZD2014 and Weekly Paclitaxel in Squamous NSCLC||Terminated||USA||2|
|NCT02831257||Phase II||Vistusertib||AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas||Completed||USA||0|
|NCT02619864||Phase Ib/II||Vistusertib||mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme||Completed||CAN||0|